Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Braz J Microbiol ; 51(3): 1021-1027, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32449119

RESUMEN

Shiga toxin-producing Escherichia coli (STEC) pathotype secretes two types of AB5 cytotoxins (Stx1 and Stx2), responsible for complications such as hemorrhagic colitis (HC) and hemolytic uremic syndrome (HUS) in infected patients, which could lead to sequels and death. Currently, there is no effective treatment against the cytotoxic effect of these toxins. However, in order to approve any therapy molecule, an animal experiment is required in order to evaluate the efficacy and safety of therapeutic approaches. The use of alternative small host models is growing among human infectious disease studies, particularly the vertebrate zebrafish model, since relevant results have been described for pathogen-host interaction. In this sense, the present work aimed to analyze the toxic effect of Shiga toxins in zebrafish embryo model in order to standardize this method in the future to be used as a fast, simple, and efficient methodology for the screening of therapeutic molecules. Herein, we demonstrated that the embryos were sensitive in a dose-dependent manner to both Stx toxins, with LD50 of 22 µg/mL for Stx1 and 33 µg/mL for Stx2, and the use of anti-Stx polyclonal antibody abolished the toxic effect. Therefore, this methodology can be a rapid alternative method for selecting promising compounds against Stx toxins, such as recombinant antibodies.


Asunto(s)
Antitoxinas/farmacología , Toxina Shiga/antagonistas & inhibidores , Animales , Evaluación Preclínica de Medicamentos , Embrión no Mamífero , Dosificación Letal Mediana , Toxina Shiga/toxicidad , Escherichia coli Shiga-Toxigénica/química , Pez Cebra
2.
Carbohydr Polym ; 212: 323-333, 2019 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-30832864

RESUMEN

Gut pathogenic enterohemorrhagic Escherichia coli (EHEC) release Shiga toxins (Stxs) as major virulence factors, which bind to globotriaosylceramide (Gb3Cer, Galα1-4 Galß1-4Glcß1-1Cer) on human target cells. The aim of this study was the production of neoglycolipids (neoGLs) using citrus pectin-derived oligosaccharides and their application as potential inhibitors of Stxs. The preparation of neoGLs starts with the reduction of the carboxylic acid group of the pectic poly(α1-4)GalUA core structure to the corresponding alcohol, followed by hydrolytic cleavage of resulting poly(α1-4)Gal into (α1-4)Galn oligosaccharides and their linkage to phosphatidylethanolamine (PE). Thin-layer chromatography overlay assays of the produced (α1-4)Galn-PE and corresponding Amadori (α1-4)Galn=PE neoGLs revealed distinguishable binding patterns for Stx1a, Stx2a, and Stx2e. Furthermore, prepared neoGLs protected Vero cells against the cytotoxic action of Stxs when applied as multivalent glycovesicles. The produced neoGLs are applicable for differentiation of Stx subtypes and represent a promising approach to combat infections of EHEC by blocking their major toxins.


Asunto(s)
Glucolípidos/farmacología , Pectinas/farmacología , Toxina Shiga/antagonistas & inhibidores , Toxina Shiga/toxicidad , Animales , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Chlorocebus aethiops , Relación Dosis-Respuesta a Droga , Glucolípidos/química , Pectinas/química , Toxina Shiga/clasificación , Células Vero
3.
Food Chem ; 227: 245-254, 2017 Jul 15.
Artículo en Inglés | MEDLINE | ID: mdl-28274429

RESUMEN

Shiga toxin (Stx)-producing, food-contaminating Escherichia coli (STEC) is a major health concern. Plant-derived pectin and pectic-oligosaccharides (POS) have been considered as prebiotics and for the protection of humans from Stx. Of five structurally different citrus pectic samples, POS1, POS2 and modified citrus pectin 1 (MCP1) were bifidogenic with similar fermentabilities in human faecal cultures and arabinose-rich POS2 had the greatest prebiotic potential. Pectic oligosaccharides also enhanced lactobacilli growth during mixed batch faecal fermentation. We demonstrated that all pectic substrates were anti-adhesive for E. coli O157:H7 binding to human HT29 cells. Lower molecular weight and deesterification enhanced the anti-adhesive activity. We showed that all pectic samples reduced Stx2 cytotoxicity in HT29 cells, as measured by the reduction of human rRNA depurination detected by our novel TaqMan-based RT-qPCR assay, with POS1 performing the best. POS1 competes with Stx2 binding to the Gb3 receptor based on ELISA results, underlining the POS anti-STEC properties.


Asunto(s)
Adhesión Bacteriana , Infecciones por Escherichia coli/microbiología , Escherichia coli O157/fisiología , Oligosacáridos/química , Pectinas/metabolismo , Prebióticos/análisis , Toxina Shiga/toxicidad , Escherichia coli O157/genética , Proteínas de Escherichia coli/genética , Proteínas de Escherichia coli/metabolismo , Heces/microbiología , Células HT29 , Humanos , Oligosacáridos/metabolismo , Pectinas/química , Toxina Shiga/metabolismo
4.
Artículo en Inglés | MEDLINE | ID: mdl-27747196

RESUMEN

Seizures and neurologic involvement have been reported in patients infected with Shiga toxin (Stx) producing E. coli, and hemolytic uremic syndrome (HUS) with neurologic involvement is associated with more severe outcome. We investigated the extent of renal and neurologic damage in mice following injection of the highly potent form of Stx, Stx2a, and less potent Stx1. As observed in previous studies, Stx2a brought about moderate to acute tubular necrosis of proximal and distal tubules in the kidneys. Brain sections stained with hematoxylin and eosin (H&E) appeared normal, although some red blood cell congestion was observed. Microglial cell responses to neural injury include up-regulation of surface-marker expression (e.g., Iba1) and stereotypical morphological changes. Mice injected with Stx2a showed increased Iba1 staining, mild morphological changes associated with microglial activation (thickening of processes), and increased microglial staining per unit area. Microglial changes were observed in the cortex, hippocampus, and amygdala regions, but not the nucleus. Magnetic resonance imaging (MRI) of Stx2a-treated mice revealed no hyper-intensities in the brain, although magnetic resonance spectroscopy (MRS) revealed significantly decreased levels of phosphocreatine in the thalamus. Less dramatic changes were observed following Stx1 challenge. Neither immortalized microvascular endothelial cells from the cerebral cortex of mice (bEnd.3) nor primary human brain microvascular endothelial cells were found to be susceptible to Stx1 or Stx2a. The lack of susceptibility to Stx for both cell types correlated with an absence of receptor expression. These studies indicate Stx causes subtle, but identifiable changes in the mouse brain.


Asunto(s)
Modelos Animales de Enfermedad , Sistema Nervioso/efectos de los fármacos , Sistema Nervioso/patología , Toxina Shiga/toxicidad , Amígdala del Cerebelo/efectos de los fármacos , Amígdala del Cerebelo/patología , Animales , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Encéfalo/patología , Proteínas de Unión al Calcio , Técnicas de Cultivo de Célula , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/patología , Proteínas de Unión al ADN , Células Endoteliales/efectos de los fármacos , Células Endoteliales/patología , Eritrocitos/efectos de los fármacos , Escherichia coli/metabolismo , Escherichia coli/patogenicidad , Síndrome Hemolítico-Urémico/microbiología , Síndrome Hemolítico-Urémico/patología , Hipocampo/efectos de los fármacos , Hipocampo/patología , Humanos , Riñón/efectos de los fármacos , Riñón/patología , Imagen por Resonancia Magnética/métodos , Masculino , Ratones , Proteínas de Microfilamentos , Microglía/efectos de los fármacos , Microglía/patología , Fosfocreatina/análisis , Conejos , Proteínas Represoras , Toxina Shiga/administración & dosificación , Toxina Shiga II/administración & dosificación , Toxina Shiga II/toxicidad , Análisis Espectral/métodos , Tálamo/química , Pruebas de Toxicidad/métodos , Factor de Necrosis Tumoral alfa/farmacología , Aumento de Peso/efectos de los fármacos , Pérdida de Peso/efectos de los fármacos
5.
Food Chem Toxicol ; 56: 381-6, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23454150

RESUMEN

Toxins of Escherichia coli (STEC) causing Uremic Hemolytic Syndrome (UHS) generate oxidative stress in human blood with more production of nitric oxide (NO) than reactive oxygen species (ROS). Shiga toxin (Stx) together with the hemolysin (Hly) increased lipid oxidation, as evaluated by malondialdehyde MDA and oxidation of proteins. The addition of Ziziphus mistol Griseb extracts decreased NO, ROS, MDA and simultaneously caused an increase in the degradation of oxidized proteins to advanced oxidation protein products (AOPPs) in controls and samples with toxins. Furthermore, the nitrosylated proteins/AOPP ratio was reduced, due to the increase of AOPP. Z. mistol Griseb extracts exhibited a high proportion of polyphenols and flavonoids, with evident correlation with ferrous reduction antioxidant potential (FRAP). The plasma of eight children with UHS showed oxidative stress and NO stimulus, comparable to the effect of toxins during the assays in vitro. UHS children presented high levels of nitrosylated proteins respect to control children of similar age. Although the degradation of oxidized proteins to AOPP rose in UHS children, the nitrosylated proteins/AOPP rate increased as a consequence of the elevated nitrosative stress observed in these patients.


Asunto(s)
Antioxidantes/farmacología , Antitoxinas/farmacología , Síndrome Hemolítico-Urémico/sangre , Extractos Vegetales/farmacología , Polifenoles/farmacología , Ziziphus/química , Productos Avanzados de Oxidación de Proteínas/sangre , Niño , Proteínas Hemolisinas/metabolismo , Humanos , Metabolismo de los Lípidos/efectos de los fármacos , Malondialdehído/sangre , Óxido Nítrico/sangre , Estrés Oxidativo/efectos de los fármacos , Especies Reactivas de Oxígeno/sangre , Toxina Shiga/metabolismo , Toxina Shiga/toxicidad , Escherichia coli Shiga-Toxigénica/metabolismo
6.
Toxicol In Vitro ; 25(1): 426-31, 2011 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-21092753

RESUMEN

Shiga toxin (Stx) and hemolysin (Hly) of Escherichia coli O157:H7 produced an increase of reactive oxygen species (ROS) in normal human blood. In vitro assays showed that stimuli of ROS with these toxins oxidized proteins to carbonyls in plasma and raised the degradation of oxidized macromolecules, with the AOPP/carbonyl relationship also increasing. The oxidative stress generated by toxins during the Hemolytic Uremic Syndrome (HUS) produced oxidation of blood proteins with a rise in advanced oxidation protein products (AOPP) in children with HUS. There was a response from the antioxidant system in these patients, evaluated through the determination of the total antioxidant capacity of plasma by the Ferric Reducing Antioxidant Power (FRAP), which reduced the stimuli of ROS during in vitro incubation with Stx or Hly. The application of natural antioxidants was sufficient to reduce in vitro the oxidative stress provoked by both toxins in blood.


Asunto(s)
Antioxidantes/metabolismo , Proteínas Sanguíneas/metabolismo , Escherichia coli O157/patogenicidad , Proteínas de Escherichia coli/toxicidad , Proteínas Hemolisinas/toxicidad , Estrés Oxidativo/efectos de los fármacos , Toxina Shiga/toxicidad , Antioxidantes/farmacología , Biomarcadores/sangre , Biomarcadores/metabolismo , Niño , Escherichia coli O157/metabolismo , Proteínas de Escherichia coli/aislamiento & purificación , Frutas/química , Proteínas Hemolisinas/aislamiento & purificación , Síndrome Hemolítico-Urémico/sangre , Síndrome Hemolítico-Urémico/metabolismo , Humanos , Leucocitos/efectos de los fármacos , Leucocitos/metabolismo , Oxidación-Reducción , Extractos Vegetales/farmacología , Prosopis/química , Carbonilación Proteica/efectos de los fármacos , Especies Reactivas de Oxígeno/sangre , Toxina Shiga/aislamiento & purificación , Ziziphus/química
7.
Clin Exp Immunol ; 155(2): 295-303, 2009 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19040610

RESUMEN

The CCL2/CCR2 chemokine/receptor axis directs the chemotaxis of infiltrating monocytes/macrophages and T cells and plays a pivotal role in tissue damage and fibrosis in kidney diseases. The eradication of the activated leucocytes should diminish the production of inflammatory mediators, limit tissue damage and ameliorate disease. A recombinant fusion protein (OPL-CCL2-LPM) comprised of the human CCL2 (monocyte chemoattractant protein-1) chemokine fused to a truncated form of the enzymatically active A1 domain of Shigella dysenteriae holotoxin (SA1) has been developed. The CCL2 portion binds specifically to CCR2-bearing leucocytes and the fusion protein enters the cells, where the SA1 moiety inhibits protein synthesis resulting in cell death. The compound was tested in a model of anti-thymocyte serum (ATS)-induced mesangioproliferative glomerulonephritis (ATS-GN). Male rats were injected with ATS on day 0 and treated intravenously with vehicle, 50 or 100 microg/kg of OPL-CCL2-LPM Q2D from days 2, 4, 6 and 8. Urine and blood were collected on days 0, 5 and 9. Animals were sacrificed on day 9. No treatment-related effects on body weight or signs of clinical toxicity were observed. Urine protein levels were decreased in treated animals. At the highest dose, histopathological analyses of kidney sections revealed maximum reductions of 36, 31, 30 and 24% for macrophage count, glomerular lesions, alpha-smooth muscle actin and fibronectin respectively. These results indicate a significant protective effect of OPL-CCL2-LPM in this model of nephritis.


Asunto(s)
Quimiocina CCL2/uso terapéutico , Glomerulonefritis Membranoproliferativa/terapia , Receptores CCR2/metabolismo , Proteínas Recombinantes de Fusión/uso terapéutico , Animales , Quimiocina CCL2/metabolismo , Quimiocina CCL2/toxicidad , Quimiotaxis de Leucocito , Relación Dosis-Respuesta a Droga , Evaluación Preclínica de Medicamentos , Glomerulonefritis Membranoproliferativa/inmunología , Glomerulonefritis Membranoproliferativa/patología , Humanos , Activación de Macrófagos , Masculino , Monocitos/metabolismo , Ratas , Ratas Sprague-Dawley , Proteínas Recombinantes de Fusión/farmacología , Proteínas Recombinantes de Fusión/toxicidad , Toxina Shiga/farmacología , Toxina Shiga/uso terapéutico , Toxina Shiga/toxicidad , Células Tumorales Cultivadas
8.
Biochem Biophys Res Commun ; 364(2): 283-8, 2007 Dec 14.
Artículo en Inglés | MEDLINE | ID: mdl-17942073

RESUMEN

Shiga toxin (Stx) is internalized by receptor-mediated endocytosis and transported retrogradely to the endoplasmic reticulum from where the enzymatically active part of the toxin is translocated to the cytosol. In this study, we have investigated the effect of polyunsaturated fatty acids (PUFA) on intoxication and retrograde transport of Stx. In HEp-2 cells, PUFA treatment inhibited Stx intoxication by a factor of 10. Moreover, both Stx internalization and endosome-to-Golgi transport were reduced by PUFA and these reductions can together explain the reduced toxicity. Also cholera toxin internalization was reduced by PUFA treatment. Finally, ricin and Pseudomonas exotoxin 1 cytotoxicity were not reduced by PUFA, demonstrating that PUFA do not cause a general block in retrograde transport to the endoplasmic reticulum. In conclusion, these results clearly demonstrate the importance of PUFA for Stx and cholera toxin trafficking.


Asunto(s)
Grasas de la Dieta/farmacología , Ácidos Grasos Insaturados/farmacología , Toxina Shiga/metabolismo , Transporte Biológico Activo , Línea Celular Tumoral , Toxina del Cólera/metabolismo , Endocitosis , Endosomas/metabolismo , Exotoxinas/toxicidad , Aparato de Golgi/metabolismo , Humanos , Transporte de Proteínas , Pseudomonas/metabolismo , Ricina/metabolismo , Ricina/toxicidad , Toxina Shiga/toxicidad , Transferrina/metabolismo
9.
Biochem Cell Biol ; 84(2): 157-66, 2006 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-16609696

RESUMEN

Shiga toxin (Stx) produced by enterohemorrhagic Escherichia coli is a critical factor in the onset of hemolytic uremic syndrome. The current study was designed to assess whether n-3 and (or) n-6 polyunsaturated fatty acids (PUFA) act as a valuable adjunct to prevent the cell injury of renal tubule cells in the emergence of HUS. The target cells, ACHN cells derived from human tubule epithelium, were cultured with each PUFA, then exposed to Stx-1 or Stx-2. The rank order of potency of PUFA to inhibit the cell death caused by each toxin was as follows: EPA > AA = DHA >> LNA. There were dose-response relations in the efficacy of each PUFA. No prophylactic effect was found in the cultures with LA. Immunofluorescence assays revealed that both the expression of the toxin receptor on ACHN cells and binding between the toxin and cells were unaffected by the PUFA. These results suggest that EPA is the most efficacious PUFA against the renal tubule cell injury caused by Stx, which may be assigned to an alteration in the intracellular pathway leading to cell death.


Asunto(s)
Ácidos Grasos Insaturados/farmacología , Túbulos Renales/efectos de los fármacos , Toxina Shiga/antagonistas & inhibidores , Toxina Shiga/toxicidad , Línea Celular , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Células Epiteliales/patología , Escherichia coli/patogenicidad , Ácidos Grasos Omega-3/farmacología , Ácidos Grasos Omega-6/farmacología , Ácidos Grasos Insaturados/administración & dosificación , Síndrome Hemolítico-Urémico/etiología , Síndrome Hemolítico-Urémico/prevención & control , Humanos , Túbulos Renales/metabolismo , Túbulos Renales/patología , Receptores de Superficie Celular/metabolismo , Toxina Shiga/metabolismo , Toxina Shiga I/toxicidad , Toxina Shiga II/toxicidad , Trihexosilceramidas/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA